

Associations of choline-related nutrients with cardiometabolic and all-cause mortality: results from 3 prospective cohort studies of blacks, whites, and Chinese

Jae Jeong Yang,¹ Loren P Lipworth,¹ Xiao-Ou Shu,¹ William J Blot,^{1,2} Yong-Bing Xiang,³ Mark D Steinwandel,² Honglan Li,³ Yu-Tang Gao,³ Wei Zheng,¹ and Danxia Yu¹

¹Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; ²International Epidemiology Field Station, Vanderbilt University Medical Center, Nashville, TN, USA; and ³State Key Laboratory of Oncogene and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

ABSTRACT

Background: Choline-related nutrients are dietary precursors of a gut microbial metabolite, trimethylamine-N-oxide, which has been linked to cardiometabolic diseases and related death. However, epidemiologic evidence on dietary choline and mortality remains limited, particularly among nonwhite populations.

Objectives: This study aimed to investigate the associations of choline-related nutrients with cardiometabolic and all-cause mortality among black and white Americans and Chinese adults.

Methods: Included were 49,858 blacks, 23,766 whites, and 134,001 Chinese, aged 40–79 y, who participated in 3 prospective cohorts and lived ≥ 1 y after enrollment. Cox regression models were used to estimate HRs and 95% CIs for cardiometabolic [e.g., ischemic heart disease (IHD), stroke, and diabetes] and all-cause deaths. To account for multiple testing, P values < 0.003 were considered significant.

Results: Mean choline intake among blacks, whites, and Chinese was 404.1 mg/d, 362.0 mg/d, and 296.8 mg/d, respectively. During a median follow-up of 11.7 y, 28,673 deaths were identified, including 11,141 cardiometabolic deaths. After comprehensive adjustments, including for overall diet quality and disease history, total choline intake was associated with increased cardiometabolic mortality among blacks and Chinese (HR for highest compared with lowest quintile: 1.26; 95% CI: 1.13, 1.40 and HR: 1.23; 95% CI: 1.11, 1.38, respectively; both P -trend < 0.001); among whites, the association was weaker (HR: 1.12; 95% CI: 0.95, 1.33; P -trend = 0.02). Total choline intake was also associated with diabetes and all-cause mortality in blacks (HR: 1.66; 95% CI: 1.26, 2.19 and HR: 1.20; 95% CI: 1.12, 1.29, respectively), with diabetes mortality in Chinese (HR: 2.24; 95% CI: 1.68, 2.97), and with IHD mortality in whites (HR: 1.31; 95% CI: 1.02, 1.69) (all P -trend < 0.001). The choline–mortality association was modified by alcohol consumption and appeared stronger among individuals with existing cardiometabolic disease. Betaine intake was associated with increased cardiometabolic mortality in Chinese only (HR: 1.16; 95% CI: 1.08, 1.25; P -trend < 0.001).

Conclusions: High choline intake was associated with increased cardiometabolic mortality in racially diverse populations. *Am J Clin Nutr* 2020;111:644–656.

Keywords: trimethylamine-N-oxide, choline, cardiometabolic mortality, all-cause mortality, multiethnic prospective cohort

Introduction

Emerging evidence implies a crucial role for the gut microbiota in human nutrition and cardiometabolic health (1–4). Trimethylamine-N-oxide (TMAO) is a gut microbial-derived metabolite of trimethylamine-containing nutrients such as choline and betaine (1, 3, 5). Recent reviews and meta-analyses have reported positive associations between elevated circulating TMAO and risks of cardiovascular disease (CVD), type 2 diabetes, and mortality, especially among patients with existing cardiometabolic conditions (2, 4, 6, 7).

Supported by Vanderbilt University Medical Center Faculty Research Scholars Program and by National Heart, Lung, and Blood Institute grant R21 HL140375. The Southern Community Cohort Study (SCCS) is supported by National Cancer Institute (NCI) grant U01 CA202979. SCCS data collection was performed by the Survey and Biospecimen Shared Resource which is supported in part by Vanderbilt-Ingram Cancer Center grant P30 CA68485. The Shanghai Women’s Health Study is supported by NCI grant UMI CA182910 (to WZ) and the Shanghai Men’s Health Study is supported by NCI grant UMI CA173640 (to X-OS).

Supplemental Tables 1–6 and Supplemental Figure 1 are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at <https://academic.oup.com/ajcn/>.

Data described in the article, code book, and analytic code will be made available upon request pending application and approval.

Address correspondence to DY (e-mail: danxia.yu@vumc.org).

Abbreviations used: CNY, Chinese yuan; CVD, cardiovascular disease; IHD, ischemic heart disease; SCCS, Southern Community Cohort Study; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study; TMAO, trimethylamine-N-oxide; USD, US dollar.

Received September 13, 2019. Accepted for publication December 2, 2019.

First published online January 8, 2020; doi: <https://doi.org/10.1093/ajcn/nqz318>.

Choline is an essential nutrient abundant in red meat, eggs, fish, and dairy, in the forms of phosphatidylcholine, free choline, glycerophosphocholine, sphingomyelin, and phosphocholine (8, 9). Betaine, a choline derivative, mostly comes from wheat products and spinach, and some comes from fish and meats (8–11). Although the recommended daily intake of choline is 550 mg for men and 425 mg for women in the United States (12), most population-based studies have reported a lower intake of ~300 mg/d among Americans (8, 10, 13–17). Studies have also indicated that the food sources of dietary choline may vary by race/ethnicity: e.g., in a multiethnic study (11), African Americans consumed more poultry-derived choline, Japanese Americans and Native Hawaiians had high fish/shellfish-derived choline, and Latinos had more legume-derived choline. On the other hand, no significant racial/ethnic variation was observed for betaine intake (11).

Currently, epidemiologic evidence on the associations of choline-related nutrients with mortality and/or incident CVD remains inconsistent. Two large US cohort studies reported positive associations of choline intake with all-cause and CVD mortality (13), but a prospective study of Japanese adults reported null associations (18). For incident CVD, several cohort studies from the United States and Europe, mostly among whites, found nonsignificant positive associations of dietary choline and betaine with CVD risk (10, 17, 19), whereas a cohort study of blacks reported a positive association of betaine intake with ischemic heart disease (IHD) and an inverse association of choline intake with ischemic stroke (14). The inconsistent findings might result from racial/ethnic differences in dietary habits/choline food sources, choline-metabolizing genetic polymorphisms, and/or gut microbial production of TMAO (20–23). However, most previous studies were conducted in a single race/ethnicity (mainly whites), thus the potential racial/ethnic differences could not be appropriately addressed. In this study including 3 prospective cohorts, the Southern Community Cohort Study (SCCS), Shanghai Men's Health Study (SMHS), and Shanghai Women's Health Study (SWHS), we compared mean daily intakes and major food sources of choline-containing compounds and betaine among black and white Americans and Chinese adults. We also investigated the associations of each choline-related nutrient with cardiometabolic-specific (i.e., IHD, stroke, and diabetes) and all-cause mortality, and further evaluated whether the associations were modified by sociodemographic characteristics, lifestyle factors, and comorbidity status.

Methods

Study population

Detailed cohort profiles of the SCCS, SMHS, and SWHS have been described elsewhere (24–26). Briefly, between March 2002 and September 2009, the SCCS enrolled a total of 84,735 primarily low-income adults, aged 40–79 y, across 12 southeastern states in the United States. Two-thirds of the study participants were blacks. The SMHS and SWHS recruited 61,480 men and 74,940 women aged 40–74 y in Shanghai, China, between 2002 and 2006 and between 1996 and 2000, respectively. Along with written informed consent, each cohort conducted a baseline survey to collect information on sociodemographic factors, lifestyle, dietary habits, and medical

history. All study participants were followed up to monitor their health and vital status (see Outcome ascertainment). These cohorts were approved by the Institutional Review Boards of Vanderbilt University, Meharry Medical College, and Shanghai Cancer Institute. The present study was approved by Scientific Committees of each cohort.

We excluded individuals who reported implausible total energy intakes (using the predefined study-specific cutoffs of <600 or >8000 kcal/d for the SCCS, <800 or >4200 kcal/d for the SMHS, and <500 or >3500 kcal/d for the SWHS) or who had invalid follow-up information. To reduce potential reverse causation, we further excluded the first year of observation including participants who died or were lost to follow-up within the first year after study enrollment. For the SCCS, participants who reported race/ethnicity other than black or white were excluded owing to the small sample size—race/ethnicity was self-identified in all 3 cohorts. After the exclusions, a total of 207,625 participants (49,858 blacks, 23,766 whites, and 134,001 Chinese) remained as the final analytic sample (**Supplemental Figure 1**).

Assessment of dietary intake

To capture habitual dietary intake at baseline, all 3 cohorts used validated FFQs comprised of foods commonly consumed in the study population. The SCCS FFQ asked about the consumption frequencies of 89 food items, which were assigned standard portion sizes using the race/ethnicity- and sex-specific portion sizes from the NHANES and the USDA Continuing Survey of Food Intakes (27–29). Total energy and nutrient intakes were calculated based on the USDA Food Composition Databases (30). The SMHS and SWHS FFQs asked about both the frequencies and quantities of consuming 81 and 77 food items, respectively. Intakes of total energy and nutrients were calculated based on the 2002 Chinese Food Composition Table (31). Total choline, choline-containing compounds (i.e., phosphatidylcholine, free choline, glycerophosphocholine, sphingomyelin, and phosphocholine), and betaine intakes were estimated using the USDA Database for the Choline Content of Common Foods for all 3 cohorts (9), given that there are no choline/betaine data in the Chinese Food Composition Tables. For the SMHS and SWHS, we also referred to the USDA National Nutrient Database for Standard Reference, as a complementary database (32). All food items in the SMHS and SWHS FFQs can be found with an exact or similar match in the USDA database. We have shown that the correlations are high between intakes of common nutrients derived from the USDA and Chinese databases (e.g., $r > 0.90$ for B vitamins and methionine), indicating the validity of using the USDA database in our Chinese population to calculate choline and betaine intakes (33, 34).

Outcome ascertainment

The primary outcome was deaths due to cardiometabolic diseases (i.e., any types of CVD and diabetes), which were further evaluated separately by deaths from IHD, stroke, and diabetes, as the secondary outcomes. The SCCS ascertained status, date, and underlying cause of death via annual linkage of the cohort to the National Death Index and Social Security Administration mortality files through 31 December, 2015. Both

the SMHS and SWHS confirmed the vital status and underlying cause of death via annual linkage to the Shanghai Vital Statistics Registry and in-person follow-up surveys through 31 December, 2016. The underlying causes of death were defined using the International Classification of Diseases, 9th and 10th Revisions (total CVD, 390–459 and I00–I99; IHD, 410–414 and I20–I25; stroke, 430–438 and I60–I69; and diabetes, 249–250 and E10–E14, respectively).

Statistical analyses

All dietary intakes were adjusted for total energy using the residual method (35). Mean intakes of choline, choline-containing compounds, and betaine (mg/d) were estimated in each race and sex group using the generalized linear model, adjusted for age and total energy intake. Partial correlation coefficients of choline-related nutrients were estimated, controlling for age, sex, and total energy intake. Baseline characteristics across total choline intake were compared using the chi-square test and the generalized linear model. Choline-related nutrients were classified into race- and sex-specific quintiles, considering substantial differences in the mean intakes across race and sex (Table 1). Cox regression models were used to estimate the HRs and 95% CIs for mortality associated with choline-related nutrients, using the lowest quintile as the reference. Follow-up time was counted from 1 y after the date of enrollment to date of death, end of follow-up, or loss to follow-up—whichever occurred first. The proportional hazard assumption was tested with goodness-of-fit tests using Schoenfeld residuals; no violation of the assumption was observed. Covariates included age (continuous), educational attainment (<12 y, high school graduation, some college, and ≥university degree), annual household income [low, lower-middle, upper-middle, and high; for the SCCS: <15,000 US dollars (USD), ≥15,000 to <25,000 USD, ≥25,000 to <50,000 USD, and ≥50,000 USD; for the SMHS: <6000 Chinese yuan (CNY), ≥6000 to <12,000 CNY, ≥12,000 to <24,000 CNY, and ≥24,000 CNY; and for the SWHS: <10,000 CNY, ≥10,000 to <20,000 CNY, ≥20,000 to <30,000 CNY, and ≥30,000 CNY], marital status (married and single/separated/divorced/widowed), smoking status (never, former, and current), smoking pack-years (continuous), alcohol consumption (none, ≤2 and >2 drinks/d in men, and ≤1 and >1 drink/d in women; 1 drink = 14 g ethanol), physical activity level (race- and sex-specific tertiles of total metabolic equivalent hours), BMI (in kg/m²; <18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, and ≥35.0 for blacks and whites and <18.5, 18.5–22.9, 23.0–27.49, and ≥27.5 for Chinese), healthy eating index developed to assess the overall diet quality and adherence to the dietary guidelines (race- and sex-specific quintiles) (29, 36), the Charlson comorbidity index using weighted comorbid conditions (0, 1, 2, 3, ≥4) (37), total energy (kcal/d; continuous), and menopausal status in women (pre and post). Given the strong association of refined carbohydrate intake with mortality and cardiometabolic diseases in the SMHS and SWHS (38, 39), refined carbohydrate intake (sex-specific quintiles) was further controlled as a potential confounder in those cohorts. Missing rates of the covariates were very low, mostly <1% of each variable—we imputed missing data using the cohort- and sex-specific median (for continuous variables) or mode (for categorical variables) values of nonmissing covariates. Linear trends across the quintiles were

tested using a continuous variable with the median values in each quintile. Stratified analyses were conducted to evaluate the effect modifications of the associations by the aforementioned covariates. Interactions between choline intake and covariates were tested by the likelihood ratio test using the multiplicative interaction term. To confirm the robustness of our findings, we further conducted a series of sensitivity analyses, excluding the first 2 y of follow-up data, excluding participants with a history of CVD, not adjusting for healthy eating index, and treating cancer deaths as competing risk events. Because of multiple comparisons across 3 racial groups and 5 uncorrelated choline-containing compounds (phosphatidylcholine and sphingomyelin were highly correlated with total choline), associations with total cardiometabolic and all-cause mortality were considered significant when *P* values were <0.003 (0.05/15). A further correction was applied when cardiometabolic deaths were divided into IHD, stroke, and diabetes, and *P* values < 0.001 were considered significant. Because the numbers of comparisons were at least doubled in stratified analyses, *P* values for significance for interactions were taken to be half of those listed above, thus <0.0015. All analyses were performed using SAS Enterprise Guide version 7.1 (SAS Institute Inc.).

Results

The mean dietary intakes of choline and betaine were 404.1 and 187.4 mg/d in blacks, 362.0 and 155.8 mg/d in whites, and 296.8 and 64.6 mg/d in Chinese, respectively (Table 1). Black men showed the highest mean intakes of total choline and betaine (494.1 and 214.7 mg/d, respectively), whereas Chinese women showed the lowest intakes (279.9 and 52.5 mg/d, respectively). Phosphatidylcholine and free choline accounted for >50% and >20% of total choline intake, respectively. The major food sources of total choline and phosphatidylcholine were red meat and eggs among blacks and whites but were eggs and soy foods among Chinese. For betaine intake, grains and vegetables were major food sources among all racial groups. No significant sex differences in major food sources were observed in each racial group (Supplemental Table 1). Total choline was strongly correlated with phosphatidylcholine and sphingomyelin ($r = 0.92$ and 0.84 in blacks, 0.89 and 0.83 in whites, and 0.93 and 0.78 in Chinese, respectively; $P < 0.001$; Supplemental Table 2), but not with other choline-containing compounds nor with betaine.

Compared with individuals who had a low choline intake, blacks and whites with a high intake had lower educational attainment, higher BMI, and more comorbidities (Table 2). However, Chinese with a high choline intake had higher levels of education and income but lower BMI than those with a low intake.

During a median follow-up of 11.7 y (9.0 y for blacks and whites and 14.0 y for Chinese), we identified 28,673 deaths (8200 for blacks, 4009 for whites, and 16,464 for Chinese), including 11,141 deaths from cardiometabolic disease (3191 for blacks, 1292 for whites, and 6658 for Chinese). After adjusting for potential confounders, total choline intake was positively associated with cardiometabolic mortality among all racial groups, significantly so in blacks and Chinese (Table 3): HR (95% CI) for the highest compared with the lowest quintile = 1.26 (1.13, 1.40) in blacks, 1.23 (1.11, 1.38) in Chinese, and 1.12

TABLE 1 Daily intakes and major food sources of choline-related nutrients in blacks, whites, and Chinese¹

	Blacks (n = 49,858)		Whites (n = 23,766)		Chinese (n = 134,001)	
	Men	Women	Men	Women	Men ²	Women ²
Total choline, mg/d	494.1 ± 102.1	345.1 ± 99.8	438.0 ± 99.8	307.6 ± 101.3	317.1 ± 94.1	279.9 ± 93.6
Phosphatidylcholine, mg/d	284.9 ± 87.8	193.4 ± 85.8	237.1 ± 85.9	162.5 ± 87.1	177.5 ± 64.8	159.5 ± 64.5
Free choline, mg/d	104.0 ± 25.2	74.2 ± 24.6	99.6 ± 24.6	71.1 ± 25.0	72.2 ± 25.0	62.2 ± 24.9
Glycerophosphocholine, mg/d	64.6 ± 18.8	46.7 ± 18.3	63.7 ± 18.4	45.2 ± 18.6	45.3 ± 15.0	37.8 ± 15.0
Sphingomyelin, mg/d	29.5 ± 9.5	21.0 ± 9.3	26.9 ± 9.3	19.3 ± 9.4	12.0 ± 4.7	10.0 ± 4.7
Phosphocholine, mg/d	13.3 ± 4.2	11.6 ± 4.1	13.4 ± 4.1	11.0 ± 4.2	10.2 ± 5.0	10.2 ± 4.9
Betaine, mg/d	214.7 ± 74.6	169.5 ± 72.9	184.2 ± 73.0	135.8 ± 74.0	79.1 ± 38.4	52.5 ± 38.2

¹Values are least-square means ± SDs adjusted for age and total energy intake unless indicated otherwise. Adjusted for total energy by using the residual method, the overall mean ± SD intakes of dietary choline and betaine were 404.1 ± 120.5 mg/d and 187.4 ± 76.0 mg/d in blacks, 362.0 ± 121.1 mg/d and 155.8 ± 76.5 mg/d in whites, and 296.8 ± 93.1 mg/d and 64.6 ± 39.4 mg/d in Chinese, respectively.

²The overall results of total choline intake were shown in a previous report (34).

TABLE 2 Baseline characteristics by dietary choline intake in blacks, whites, and Chinese¹

	Blacks (n = 49,858)					Whites (n = 23,766)					Chinese (n = 134,001)				
	Q1	Q3	Q5	Q1	Q3	Q5	Q1	Q3	Q5	Q1	Q3	Q5	Q1	Q3	Q5
Total choline intake, mg/d	280.3 ± 61.9	394.9 ± 73.4	556.4 ± 126.5	250.0 ± 56.3	349.5 ± 62.3	491.7 ± 113.9	179.9 ± 33.0	290.5 ± 19.3	430.9 ± 72.5	136.7 ± 39.9	219.4 ± 55.2	351.4 ± 107.8	116.0 ± 34.6	163.4 ± 23.3	254.0 ± 56.2
Phosphatidylcholine intake, mg/d	75.5 ± 24.7	87.2 ± 26.0	95.0 ± 36.3	70.1 ± 22.7	83.4 ± 22.8	91.5 ± 36.8	44.7 ± 12.1	65.3 ± 16.1	92.5 ± 29.4	45.7 ± 14.6	54.2 ± 17.6	61.1 ± 26.5	42.4 ± 15.2	40.9 ± 10.7	53.9 ± 20.1
Free choline intake, mg/d	14.7 ± 5.1	23.5 ± 6.3	36.5 ± 11.4	13.8 ± 4.7	21.5 ± 5.6	32.4 ± 9.9	6.2 ± 2.4	10.7 ± 2.8	16.1 ± 5.0	9.4 ± 3.4	12.5 ± 3.8	14.4 ± 4.9	9.3 ± 3.2	10.1 ± 3.5	14.6 ± 5.5
Glycerophosphocholine intake, mg/d	153.2 ± 68.9	192.5 ± 76.9	210.1 ± 92.2	130.8 ± 59.2	161.0 ± 61.2	169.9 ± 72.5	52.8 ± 38.2	64.7 ± 36.3	77.1 ± 45.0	51.0 ± 8.5	51.9 ± 8.5	51.9 ± 8.5	55.1 ± 9.6	52.9 ± 9.3	52.3 ± 9.4
Betaine intake, mg/d	40.8	40.8	40.8	38.9	38.9	38.9	45.5	45.5	45.5	30.1 ± 7.4	30.6 ± 7.5	31.1 ± 7.8	29.0 ± 7.0	23.8 ± 3.2	23.7 ± 3.2
Men, %	62.9	65.6	66.8	74.9	76.2	78.7	61.5	46.5	42.4	62.9	65.6	66.8	74.9	76.2	78.7
BMI, kg/m ²	1.7 ± 1.4	1.8 ± 1.5	2.0 ± 1.5	2.0 ± 1.5	2.1 ± 1.6	2.2 ± 1.6	0.6 ± 0.9	0.5 ± 0.9	0.6 ± 1.0	1.7 ± 1.4	1.8 ± 1.5	2.0 ± 1.5	2.0 ± 1.5	2.1 ± 1.6	2.2 ± 1.6
Menopause, % (only among women)	30.7	29.3	34.9	24.8	20.5	25.3	64.2	47.6	42.5	30.7	29.3	34.9	24.8	20.5	25.3
Charlson comorbidity index	33.0	34.3	34.7	32.3	31.6	30.6	25.3	32.8	34.9	25.8	25.7	22.0	25.4	26.4	25.8
Educational attainment, %	10.5	10.8	8.4	17.5	21.5	18.4	4.2	8.3	9.8	10.5	10.8	8.4	17.5	21.5	18.4
< High school graduation	59.1	58.3	62.2	49.5	43.0	48.2	19.2	13.1	13.0	59.1	58.3	62.2	49.5	43.0	48.2
High school graduation	22.3	22.4	21.8	18.4	19.3	18.2	44.7	39.9	36.6	22.3	22.4	21.8	18.4	19.3	18.2
Some college	12.7	13.2	11.5	15.7	17.6	16.5	27.0	32.5	32.8	12.7	13.2	11.5	15.7	17.6	16.5
≥ University degree	5.9	6.2	4.5	16.4	20.1	17.1	9.1	14.5	17.6	5.9	6.2	4.5	16.4	20.1	17.1
Annual household income, ² %	72.4	70.0	70.5	53.3	50.8	52.0	90.9	93.8	92.7	72.4	70.0	70.5	53.3	50.8	52.0
Smoking status, %	38.0	38.2	37.0	32.9	34.6	32.5	64.7	67.8	66.5	38.0	38.2	37.0	32.9	34.6	32.5
Never	18.8	20.1	21.5	25.7	29.6	31.3	5.5	5.0	5.1	18.8	20.1	21.5	25.7	29.6	31.3
Former	43.1	41.7	41.4	41.4	35.8	36.2	29.9	27.2	28.4	43.1	41.7	41.4	41.4	35.8	36.2
Current	19.6 ± 18.7	18.1 ± 17.6	19.0 ± 18.8	32.8 ± 27.5	30.2 ± 26.0	34.0 ± 29.1	24.5 ± 16.6	23.5 ± 16.2	24.6 ± 16.6	19.6 ± 18.7	18.1 ± 17.6	19.0 ± 18.8	32.8 ± 27.5	30.2 ± 26.0	34.0 ± 29.1
Smoking pack-years, among ever-smokers	46.1	45.8	46.4	50.7	49.1	51.0	88.3	85.1	76.3	46.1	45.8	46.4	50.7	49.1	51.0
Alcohol consumption, ³ %	32.2	35.4	36.6	34.9	39.7	36.5	7.0	9.8	13.0	32.2	35.4	36.6	34.9	39.7	36.5
None	21.8	18.8	17.0	14.4	11.2	12.6	4.7	5.1	10.6	21.8	18.8	17.0	14.4	11.2	12.6
Moderate drinking	22.5 ± 18.8	23.4 ± 19.4	21.9 ± 18.8	21.5 ± 17.6	22.2 ± 18.1	20.9 ± 17.5	86.3 ± 47.6	85.4 ± 46.5	84.6 ± 47.4	22.5 ± 18.8	23.4 ± 19.4	21.9 ± 18.8	21.5 ± 17.6	22.2 ± 18.1	20.9 ± 17.5
Heavy drinking	54.9 ± 12.4	59.2 ± 11.4	57.5 ± 11.3	53.3 ± 13.1	59.3 ± 12.2	58.2 ± 12.0	32.5 ± 4.0	34.4 ± 4.3	32.1 ± 4.6	54.9 ± 12.4	59.2 ± 11.4	57.5 ± 11.3	53.3 ± 13.1	59.3 ± 12.2	58.2 ± 12.0
Healthy eating index															

¹Values are mean ± SD of continuous variables or proportion (%) of categorical variables. Intakes were based on the race- and sex-specific Qs adjusted for total energy using the residual method. Differences across Qs were all statistically significant ($P < 0.003$) except for sex for all 3 racial groups and marital status for whites. CNY, Chinese yuan; MET, metabolic equivalent of task; Q, quintile; USD, US dollar.

²Annual household income was defined as low, lower-middle, upper-middle, and high; for the Southern Community Cohort Study: <15,000 USD, ≥15,000 to <25,000 USD, ≥25,000 to <50,000 USD, and ≥50,000 USD; for the Shanghai Men's Health Study: <6000 CNY, ≥6000 to <12,000 CNY, ≥12,000 to <24,000 CNY, and ≥24,000 CNY; and for the Shanghai Women's Health Study: <10,000 CNY, ≥10,000 to <20,000 CNY, ≥20,000 to <30,000 CNY, and ≥30,000 CNY.

³Heavy drinking was defined as alcohol consumption of >2 drinks/d in men or >1 drink/d in women; and moderate drinking was defined as alcohol consumption of >0 to ≤2 drinks/d in men or >0 to ≤1 drink/d in women.

TABLE 3 Risk of cardiometabolic death by intakes of choline-related nutrients¹

	Blacks (<i>n</i> = 49,858)			Whites (<i>n</i> = 23,766)			Chinese (<i>n</i> = 134,001)		
	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ²	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ²	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ^{2,3}
Total choline									
Q1	553	263.8	1 (ref.)	244	236.9	1 (ref.)	1874	185.7	1 (ref.)
Q2	590	310.1	1.09 (0.97, 1.22)	210	277.9	0.85 (0.71, 1.02)	1318	245.0	1.04 (0.96, 1.12)
Q3	617	348.6	1.12 (1.00, 1.26)	241	311.9	0.94 (0.79, 1.13)	1119	289.3	1.01 (0.92, 1.10)
Q4	674	397.1	1.18 (1.05, 1.32)	265	353.2	1.01 (0.84, 1.20)	1123	336.3	1.09 (0.98, 1.20)
Q5	757	531.7	1.26 (1.13, 1.40)	332	461.7	1.12 (0.95, 1.33)	1224	414.0	1.23 (1.11, 1.38)
<i>P</i> -trend ⁴			<0.001			0.02			<0.001
Phosphatidylcholine									
Q1	579	123.3	1 (ref.)	233	102.8	1 (ref.)	1859	92.9	1 (ref.)
Q2	579	161.4	1.03 (0.92, 1.16)	216	134.0	0.94 (0.78, 1.14)	1295	130.9	0.99 (0.92, 1.07)
Q3	625	194.1	1.10 (0.98, 1.23)	239	161.5	1.00 (0.83, 1.20)	1148	161.8	1.03 (0.95, 1.12)
Q4	621	236.2	1.07 (0.95, 1.20)	268	197.8	1.06 (0.88, 1.26)	1120	194.8	1.07 (0.98, 1.17)
Q5	787	353.7	1.27 (1.14, 1.41)	336	301.2	1.19 (1.00, 1.41)	1236	246.2	1.07 (0.97, 1.18)
<i>P</i> -trend ⁴			<0.001			0.008			0.09
Free choline									
Q1	557	57.0	1 (ref.)	267	54.1	1 (ref.)	1653	39.8	1 (ref.)
Q2	602	66.3	1.06 (0.94, 1.20)	259	63.9	0.90 (0.75, 1.07)	1205	52.3	1.05 (0.97, 1.14)
Q3	644	74.3	1.14 (1.01, 1.29)	253	72.0	0.89 (0.74, 1.07)	1119	62.8	1.11 (1.02, 1.21)
Q4	713	84.6	1.28 (1.13, 1.45)	263	81.4	0.92 (0.76, 1.11)	1183	75.6	1.11 (1.01, 1.21)
Q5	675	114.7	1.26 (1.11, 1.43)	250	105.4	0.89 (0.73, 1.08)	1498	97.8	1.26 (1.15, 1.38)
<i>P</i> -trend ⁴			<0.001			0.69			<0.001
Glycerophosphocholine									
Q1	578	34.5	1 (ref.)	286	31.1	1 (ref.)	2132	25.0	1 (ref.)
Q2	608	40.6	1.05 (0.94, 1.18)	266	38.6	0.94 (0.79, 1.11)	1448	32.6	0.97 (0.90, 1.04)
Q3	623	46.1	1.03 (0.92, 1.16)	248	45.1	0.85 (0.71, 1.01)	1189	39.2	0.93 (0.86, 1.01)
Q4	670	53.7	1.09 (0.97, 1.22)	258	53.7	0.86 (0.72, 1.02)	1005	46.3	0.87 (0.79, 0.95)
Q5	712	75.9	1.11 (0.99, 1.25)	234	77.0	0.83 (0.69, 1.00)	884	58.9	0.87 (0.79, 0.97)
<i>P</i> -trend ⁴			0.05			0.06			0.002
Sphingomyelin									
Q1	577	12.8	1 (ref.)	247	12.1	1 (ref.)	2152	5.5	1 (ref.)
Q2	582	17.6	1.03 (0.92, 1.16)	212	16.3	0.91 (0.75, 1.09)	1399	8.3	0.94 (0.88, 1.01)
Q3	654	21.3	1.14 (1.02, 1.28)	260	19.6	1.08 (0.91, 1.29)	1184	10.4	0.92 (0.85, 1.00)
Q4	647	26.0	1.12 (1.00, 1.25)	264	23.6	1.08 (0.91, 1.29)	964	12.8	0.80 (0.73, 0.88)
Q5	731	38.1	1.23 (1.10, 1.37)	309	33.8	1.15 (0.97, 1.37)	959	16.8	0.88 (0.79, 0.98)
<i>P</i> -trend ⁴			<0.001			0.03			0.001
Phosphocholine									
Q1	540	7.4	1 (ref.)	259	7.3	1 (ref.)	1740	4.7	1 (ref.)
Q2	594	9.8	1.05 (0.93, 1.19)	258	9.6	0.99 (0.82, 1.18)	1204	7.3	1.02 (0.94, 1.10)
Q3	638	11.6	1.11 (0.98, 1.25)	245	11.3	0.91 (0.75, 1.10)	1082	9.5	1.03 (0.94, 1.12)
Q4	675	13.9	1.13 (0.99, 1.28)	266	13.4	0.98 (0.81, 1.20)	1145	12.0	1.07 (0.98, 1.17)
Q5	744	17.8	1.22 (1.07, 1.40)	264	17.5	1.00 (0.81, 1.23)	1487	16.5	1.13 (1.03, 1.23)
<i>P</i> -trend ⁴			0.002			0.82			0.003
Betaine									
Q1	620	104.2	1 (ref.)	285	86.7	1 (ref.)	1700	27.7	1 (ref.)
Q2	641	137.1	1.05 (0.94, 1.18)	239	111.6	0.85 (0.71, 1.01)	1264	41.3	0.98 (0.91, 1.06)
Q3	626	165.2	1.03 (0.92, 1.16)	263	133.6	0.93 (0.79, 1.11)	1232	52.2	1.08 (1.00, 1.16)
Q4	652	205.9	1.04 (0.92, 1.16)	257	166.3	0.85 (0.72, 1.02)	1096	68.3	1.05 (0.97, 1.13)
Q5	652	287.0	0.99 (0.88, 1.12)	248	240.6	0.83 (0.69, 0.99)	1366	114.0	1.16 (1.08, 1.25)
<i>P</i> -trend ⁴			0.73			0.08			<0.001

¹Death from any kinds of cardiovascular disease and diabetes. Intakes were based on the race- and sex-specific Qs. Q, quintile.

²Adjusted for age, educational attainment, annual household income, marital status, smoking status, smoking pack-years, alcohol consumption, physical activity level, obesity status, healthy eating index, Charlson comorbidity index, intake of total energy, and menopausal status in women.

³Intake of refined carbohydrate was further adjusted for the Chinese population.

⁴To adjust for multiple comparisons across the 3 racial groups and different choline-related nutrients, trend *P* values < 0.003 (0.05/15) were considered significant.

(0.95, 1.33) in whites. All choline-related nutrients, except glycerophosphocholine and betaine, were associated with a 22–27% increased risk of cardiometabolic mortality among blacks, when comparing the highest with the lowest quintiles.

Among whites, phosphatidylcholine was significantly associated with a 19% increased risk. Among Chinese, free choline, phosphocholine, and betaine were associated with a 13–26% increased risk, whereas glycerophosphocholine and sphingomyelin

showed associations with decreased risk of cardiometabolic mortality.

We further examined choline intakes in relation to cause-specific mortality due to IHD, stroke, and diabetes (Table 4). Blacks showed strong positive associations of total choline, phosphatidylcholine, free choline, and sphingomyelin with diabetes mortality—HRs for the highest compared with the lowest quintiles were 1.59–1.79 with all P -trend < 0.001 —but no associations with IHD or stroke mortality. Among whites, the highest quintiles of total choline, phosphatidylcholine, and sphingomyelin were associated with 1.31- to 1.52-fold increased HRs for IHD mortality with all P -trend < 0.001 , but there were no associations with diabetes or stroke mortality. Among Chinese, total choline, phosphatidylcholine, free choline, and phosphocholine were all associated with diabetes mortality: the HRs were 1.51–2.24; betaine was associated with IHD mortality with an HR of 1.24 (all P -trend < 0.001).

Similar patterns, but with associations of attenuated magnitudes, were found for all-cause mortality (Table 5). Among blacks, the HR (95% CI) for the highest compared with the lowest quintile was 1.20 (1.12, 1.29) (P -trend < 0.001). Among Chinese, a positive association was suggested, but the P -trend value failed to reach statistical significance after accounting for multiple comparisons (HR: 1.08; 95% CI: 1.00, 1.15 for the highest compared with the lowest quintile; P -trend = 0.04). However, no associations of total choline with all-cause mortality were found among whites.

We further conducted stratified analyses by sociodemographic factors, lifestyle, and comorbidity status (Figure 1); the analyses used a pooled data set of the 3 racial groups, given that there was no significant heterogeneity across races in the total choline–cardiometabolic mortality association, and the pooled analysis increased the statistical power. After accounting for multiple comparisons, we found that the associations of total choline with cardiometabolic and all-cause mortality were only significant if the participants were not heavy drinkers (P -interaction = 0.001 and 0.007, respectively). Furthermore, the choline–mortality associations were likely to be stronger among individuals with a history of diabetes or CVD, but P -interaction did not meet the multiple comparison cutoff for significance. Potential nonlinear associations were assessed via restricted cubic splines among total study populations: results suggested a linear association of total choline intake with cardiometabolic mortality and a nonlinear association with all-cause mortality (Figure 2).

Results from the sensitivity analyses indicated that overall patterns of the choline–mortality associations were similar even after excluding further follow-up data and prevalent cases of CVD or after applying different adjustment methods and competing risk analyses (Supplemental Tables 3–6).

Discussion

In this prospective analysis, including $>200,000$ men and women from racially diverse populations, we found that high intakes of total choline and certain choline-containing compounds were associated with increased risk of cardiometabolic mortality, especially diabetes and IHD mortality. Overall, the choline–cardiometabolic mortality associations appeared to be more evident among blacks and Chinese than among whites. In

addition, the choline–cardiometabolic mortality association was modified by alcohol drinking status and seemed more pronounced among individuals with a history of diabetes or CVD.

Choline is an essential nutrient for normal functions of cell membranes and muscle, cholinergic neurotransmission, lipid transport, and one-carbon metabolism (40). Choline deficiency can lead to fatty liver disease, hemorrhagic kidney necrosis, muscle damage, and organ dysfunction (40–42). Despite its vital role in the human body, choline can also serve as a dietary precursor of TMAO via the gut microbial metabolism (2), a potential risk factor for CVD and related deaths. To date, epidemiological findings regarding choline intake and cardiometabolic disease and/or mortality have been mixed. In line with our findings, the Nurses' Health Study and Health Professionals Follow-up Study observed significant positive associations of dietary phosphatidylcholine with CVD and all-cause mortality (13)—the corresponding HRs (95% CIs) were 1.26 (1.15, 1.39) and 1.11 (1.06, 1.17), respectively. However, the Atherosclerosis Risk in Communities Study and the European Prospective Investigation into Cancer and Nutrition study, composed of mostly white populations, found no association of dietary choline intake with incident CVD (10, 19). On the contrary, the Jackson Heart Study, which consisted of 3924 blacks, reported an inverse association of choline intake with incident stroke and a positive association of betaine intake with IHD risk (14). Relevant evidence from Asian populations has been very limited: a prospective study conducted in Japan found no association between choline intake and mortality (18). Overall, a recent meta-analysis including these prospective studies, comprising a total of 184,010 participants with 18,076 incident CVD events and 5343 CVD deaths, suggested no significant associations of dietary choline or betaine intake with CVD risk or mortality (43).

In the present study, we found significant positive associations between choline intake and certain cardiometabolic mortality (i.e., IHD and diabetes) among blacks, whites, and Chinese, after adjusting for many disease risk factors and overall diet quality. Although there was no significant heterogeneity across races in the association, the magnitude and pattern of the associations between choline-related nutrients and cardiometabolic mortality appeared different across races. The most consistent and pronounced associations were observed among blacks for total choline and choline-containing compounds with both cardiometabolic and all-cause mortality. The associations were generally weaker among whites, with the primary observed association between phosphatidylcholine/sphingomyelin and IHD mortality. Among Chinese, the association of total choline with diabetes mortality was the strongest, whereas betaine intake also showed significant positive associations with cardiometabolic and all-cause mortality. Distinct from other choline-related nutrients, sphingomyelin and glycerophosphocholine were inversely associated with stroke and all-cause mortality among Chinese, but not among blacks or whites. Epidemiologic and/or biological evidence to date on the role of choline-containing compounds in human cardiometabolic health remains limited. One possible explanation for the variation we observed is that the choline–mortality association might be modified by different habitual diets, food sources of choline, and comorbidity status, which can modulate the gut microbial ability for producing TMAO (20, 21). As shown in Table 1, although red meat and eggs are the primary dietary sources of choline, other major food

TABLE 4 Risk of death from ischemic heart disease, stroke, and diabetes by intakes of choline-related nutrients¹

	Ischemic heart disease					Stroke					Diabetes				
	Blacks ²		Whites ²		Chinese ^{2,3}	Blacks ²		Whites ²		Chinese ^{2,3}	Blacks ²		Whites ²		Chinese ^{2,3}
	I (ref.)	0.73 (0.54, 0.99)	1.02 (0.89, 1.18)	1.04 (0.76, 1.43)	1 (ref.)	1.09 (0.62, 1.89)	1.05 (0.93, 1.18)	1 (ref.)	1 (ref.)	1 (ref.)	1.03 (0.75, 1.41)	0.71 (0.42, 1.18)	1 (ref.)	0.71 (0.42, 1.18)	1.23 (0.98, 1.54)
Total choline															
Q1	1.12 (0.92, 1.37)	0.73 (0.54, 0.99)	1.02 (0.89, 1.18)	1.04 (0.76, 1.43)	1 (ref.)	1.09 (0.62, 1.89)	1.05 (0.93, 1.18)	1 (ref.)	1 (ref.)	1.03 (0.75, 1.41)	0.71 (0.42, 1.18)	1 (ref.)	0.71 (0.42, 1.18)	1.23 (0.98, 1.54)	
Q2	0.96 (0.78, 1.18)	0.92 (0.69, 1.22)	1.13 (0.97, 1.33)	1.19 (0.87, 1.61)	1.10 (0.63, 1.92)	0.89 (0.77, 1.01)	0.89 (0.77, 1.01)	1.13 (0.83, 1.54)	0.75 (0.45, 1.24)	1.13 (0.83, 1.54)	0.75 (0.45, 1.24)	1.13 (0.83, 1.54)	0.75 (0.45, 1.24)	1.26 (0.98, 1.62)	
Q3	1.05 (0.86, 1.28)	1.15 (0.88, 1.50)	1.14 (0.96, 1.36)	1.22 (0.90, 1.65)	0.99 (0.56, 1.75)	0.99 (0.85, 1.15)	0.99 (0.85, 1.15)	1.29 (0.96, 1.73)	0.95 (0.59, 1.53)	1.29 (0.96, 1.73)	0.95 (0.59, 1.53)	1.29 (0.96, 1.73)	0.95 (0.59, 1.53)	1.50 (1.14, 1.97)	
Q4	1.08 (0.89, 1.32)	1.31 (1.02, 1.69)	1.29 (1.06, 1.56)	1.20 (0.89, 1.62)	1.12 (0.65, 1.93)	1.02 (0.87, 1.21)	1.02 (0.87, 1.21)	1.66 (1.26, 2.19)	0.96 (0.61, 1.51)	1.66 (1.26, 2.19)	0.96 (0.61, 1.51)	1.66 (1.26, 2.19)	0.96 (0.61, 1.51)	2.24 (1.68, 2.97)	
P-trend ⁴	0.63	<0.001	0.01	0.22	0.68	0.93	0.93	<0.001	0.72	<0.001	<0.001	<0.001	0.72	<0.001	
Phosphatidylcholine															
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	
Q2	1.06 (0.87, 1.29)	1.00 (0.74, 1.34)	1.02 (0.89, 1.17)	0.79 (0.57, 1.09)	0.81 (0.45, 1.46)	0.98 (0.87, 1.09)	0.98 (0.87, 1.09)	1.21 (0.89, 1.65)	0.91 (0.54, 1.53)	1.21 (0.89, 1.65)	0.91 (0.54, 1.53)	1.21 (0.89, 1.65)	0.91 (0.54, 1.53)	1.02 (0.82, 1.27)	
Q3	1.01 (0.82, 1.23)	1.01 (0.75, 1.35)	1.12 (0.96, 1.30)	1.16 (0.86, 1.55)	1.15 (0.67, 1.98)	0.94 (0.83, 1.06)	0.94 (0.83, 1.06)	1.13 (0.83, 1.55)	1.01 (0.61, 1.65)	1.13 (0.83, 1.55)	1.01 (0.61, 1.65)	1.13 (0.83, 1.55)	1.01 (0.61, 1.65)	1.12 (0.89, 1.43)	
Q4	0.91 (0.74, 1.12)	1.27 (0.96, 1.67)	1.12 (0.96, 1.31)	1.08 (0.80, 1.46)	1.17 (0.69, 2.00)	0.97 (0.85, 1.11)	0.97 (0.85, 1.11)	1.34 (0.99, 1.80)	0.96 (0.58, 1.58)	1.34 (0.99, 1.80)	0.96 (0.58, 1.58)	1.34 (0.99, 1.80)	0.96 (0.58, 1.58)	1.34 (1.06, 1.71)	
Q5	1.11 (0.91, 1.35)	1.52 (1.17, 1.98)	1.18 (0.99, 1.39)	1.16 (0.87, 1.56)	0.96 (0.55, 1.66)	0.90 (0.78, 1.04)	0.90 (0.78, 1.04)	1.67 (1.26, 2.22)	1.10 (0.69, 1.75)	1.67 (1.26, 2.22)	1.10 (0.69, 1.75)	1.67 (1.26, 2.22)	1.10 (0.69, 1.75)	1.51 (1.17, 1.94)	
P-trend ⁴	0.74	<0.001	0.05	0.12	0.82	0.20	0.20	<0.001	0.66	<0.001	<0.001	<0.001	0.66	<0.001	
Free choline															
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	
Q2	1.08 (0.88, 1.34)	0.86 (0.66, 1.12)	0.96 (0.83, 1.11)	1.08 (0.80, 1.47)	0.81 (0.45, 1.47)	1.07 (0.95, 1.20)	1.07 (0.95, 1.20)	1.09 (0.80, 1.49)	0.88 (0.55, 1.43)	1.09 (0.80, 1.49)	0.88 (0.55, 1.43)	1.09 (0.80, 1.49)	0.88 (0.55, 1.43)	1.35 (1.07, 1.69)	
Q3	1.14 (0.92, 1.42)	0.92 (0.70, 1.21)	0.99 (0.85, 1.16)	0.96 (0.70, 1.33)	1.37 (0.79, 2.39)	1.13 (0.99, 1.28)	1.13 (0.99, 1.28)	1.33 (0.97, 1.82)	0.65 (0.38, 1.12)	1.33 (0.97, 1.82)	0.65 (0.38, 1.12)	1.33 (0.97, 1.82)	0.65 (0.38, 1.12)	1.52 (1.20, 1.93)	
Q4	1.34 (1.07, 1.66)	0.90 (0.67, 1.19)	1.11 (0.95, 1.30)	1.03 (0.74, 1.43)	1.14 (0.63, 2.06)	1.06 (0.93, 1.21)	1.06 (0.93, 1.21)	1.64 (1.20, 2.24)	1.03 (0.63, 1.70)	1.64 (1.20, 2.24)	1.03 (0.63, 1.70)	1.64 (1.20, 2.24)	1.03 (0.63, 1.70)	1.54 (1.21, 1.96)	
Q5	1.26 (1.00, 1.58)	0.94 (0.70, 1.26)	1.21 (1.03, 1.42)	1.08 (0.77, 1.52)	1.05 (0.56, 1.97)	1.25 (1.09, 1.43)	1.25 (1.09, 1.43)	1.59 (1.14, 2.22)	0.89 (0.52, 1.52)	1.59 (1.14, 2.22)	0.89 (0.52, 1.52)	1.59 (1.14, 2.22)	0.89 (0.52, 1.52)	1.67 (1.31, 2.14)	
P-trend ⁴	0.03	0.89	0.003	0.84	0.51	0.003	0.003	<0.001	0.99	<0.001	<0.001	<0.001	0.99	<0.001	
Glycerophosphocholine															
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	
Q2	1.03 (0.85, 1.26)	1.07 (0.84, 1.37)	1.10 (0.97, 1.24)	0.83 (0.61, 1.13)	1.10 (0.63, 1.92)	0.88 (0.79, 0.98)	0.88 (0.79, 0.98)	1.12 (0.83, 1.52)	0.58 (0.35, 0.96)	1.12 (0.83, 1.52)	0.58 (0.35, 0.96)	1.12 (0.83, 1.52)	0.58 (0.35, 0.96)	1.16 (0.95, 1.41)	
Q3	0.99 (0.81, 1.21)	0.78 (0.60, 1.03)	0.99 (0.86, 1.15)	0.79 (0.58, 1.07)	1.08 (0.61, 1.89)	0.86 (0.77, 0.97)	0.86 (0.77, 0.97)	1.27 (0.94, 1.71)	0.89 (0.57, 1.39)	1.27 (0.94, 1.71)	0.89 (0.57, 1.39)	1.27 (0.94, 1.71)	0.89 (0.57, 1.39)	1.13 (0.90, 1.42)	
Q4	0.97 (0.79, 1.19)	0.68 (0.51, 0.89)	1.03 (0.88, 1.20)	0.95 (0.70, 1.27)	1.16 (0.66, 2.01)	0.70 (0.61, 0.81)	0.70 (0.61, 0.81)	1.24 (0.92, 1.67)	0.86 (0.55, 1.35)	1.24 (0.92, 1.67)	0.86 (0.55, 1.35)	1.24 (0.92, 1.67)	0.86 (0.55, 1.35)	1.19 (0.93, 1.53)	
Q5	0.96 (0.78, 1.18)	0.89 (0.68, 1.17)	0.95 (0.80, 1.13)	0.99 (0.74, 1.34)	1.00 (0.56, 1.81)	0.73 (0.63, 0.86)	0.73 (0.63, 0.86)	1.41 (1.05, 1.90)	0.61 (0.36, 1.02)	1.41 (1.05, 1.90)	0.61 (0.36, 1.02)	1.41 (1.05, 1.90)	0.61 (0.36, 1.02)	1.44 (1.11, 1.87)	
P-trend ⁴	0.68	0.11	0.39	0.58	0.84	<0.001	<0.001	0.02	0.21	0.02	0.21	0.02	0.21	0.004	

(Continued)

TABLE 4 (Continued)

	Ischemic heart disease			Stroke			Diabetes		
	Blacks ²	Whites ²	Chinese ^{2,3}	Blacks ²	Whites ²	Chinese ^{2,3}	Blacks ²	Whites ²	Chinese ^{2,3}
Sphingomyelin									
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Q2	0.82 (0.67, 1.00)	0.86 (0.64, 1.15)	1.07 (0.95, 1.22)	1.04 (0.77, 1.41)	0.68 (0.38, 1.21)	0.85 (0.77, 0.95)	1.40 (1.03, 1.92)	0.71 (0.42, 1.20)	1.05 (0.86, 1.29)
Q3	0.99 (0.82, 1.20)	1.20 (0.91, 1.58)	1.00 (0.86, 1.16)	1.14 (0.84, 1.54)	1.15 (0.70, 1.91)	0.84 (0.74, 0.95)	1.47 (1.08, 2.01)	0.99 (0.62, 1.59)	1.18 (0.95, 1.48)
Q4	0.88 (0.72, 1.08)	1.11 (0.84, 1.46)	0.97 (0.83, 1.14)	1.27 (0.95, 1.71)	0.91 (0.53, 1.57)	0.65 (0.56, 0.75)	1.43 (1.05, 1.94)	1.11 (0.70, 1.75)	1.02 (0.79, 1.32)
Q5	0.98 (0.81, 1.20)	1.48 (1.14, 1.91)	1.01 (0.83, 1.22)	1.09 (0.80, 1.48)	0.91 (0.53, 1.56)	0.73 (0.62, 0.86)	1.79 (1.33, 2.41)	0.80 (0.50, 1.29)	1.20 (0.91, 1.60)
<i>P</i> -trend ⁴	0.99	<0.001	0.72	0.37	0.99	<0.001	<0.001	0.70	0.16
Phosphocholine									
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Q2	1.16 (0.94, 1.44)	1.28 (0.98, 1.69)	0.93 (0.81, 1.07)	1.06 (0.78, 1.45)	1.11 (0.65, 1.90)	1.03 (0.92, 1.16)	0.94 (0.67, 1.31)	0.67 (0.40, 1.13)	1.33 (1.06, 1.66)
Q3	1.18 (0.94, 1.47)	1.15 (0.86, 1.54)	0.95 (0.81, 1.11)	1.01 (0.73, 1.41)	0.71 (0.39, 1.32)	1.02 (0.90, 1.16)	1.08 (0.78, 1.50)	0.80 (0.48, 1.32)	1.39 (1.09, 1.77)
Q4	1.10 (0.87, 1.38)	1.17 (0.86, 1.59)	1.09 (0.94, 1.28)	0.87 (0.71, 1.24)	0.90 (0.49, 1.67)	0.96 (0.84, 1.10)	1.36 (0.98, 1.90)	0.84 (0.50, 1.40)	1.51 (1.19, 1.92)
Q5	1.24 (0.97, 1.58)	1.22 (0.89, 1.68)	1.13 (0.97, 1.31)	1.04 (0.72, 1.50)	1.00 (0.52, 1.90)	1.04 (0.91, 1.18)	1.38 (0.98, 1.95)	0.67 (0.38, 1.18)	1.65 (1.31, 2.07)
<i>P</i> -trend ⁴	0.18	0.52	0.01	0.90	0.97	0.75	0.008	0.40	<0.001
Betaine									
Q1	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)	1 (ref.)
Q2	1.07 (0.88, 1.31)	0.95 (0.73, 1.22)	1.10 (0.97, 1.26)	1.04 (0.77, 1.42)	0.45 (0.25, 0.83)	0.90 (0.81, 1.01)	1.01 (0.75, 1.35)	0.75 (0.46, 1.21)	0.98 (0.80, 1.21)
Q3	1.09 (0.89, 1.33)	0.80 (0.61, 1.05)	1.16 (1.01, 1.32)	1.29 (0.96, 1.74)	0.79 (0.47, 1.32)	1.01 (0.90, 1.13)	1.05 (0.78, 1.41)	0.98 (0.62, 1.54)	1.15 (0.94, 1.41)
Q4	1.13 (0.92, 1.39)	0.81 (0.62, 1.06)	1.20 (1.05, 1.38)	1.09 (0.80, 1.48)	0.78 (0.47, 1.31)	0.91 (0.81, 1.03)	1.05 (0.78, 1.41)	0.78 (0.49, 1.26)	1.07 (0.87, 1.33)
Q5	1.07 (0.87, 1.32)	0.93 (0.71, 1.22)	1.24 (1.09, 1.42)	0.89 (0.64, 1.23)	0.79 (0.46, 1.36)	1.12 (1.01, 1.25)	1.36 (1.02, 1.81)	0.60 (0.36, 1.01)	1.05 (0.85, 1.29)
<i>P</i> -trend ⁴	0.60	0.44	<0.001	0.41	0.91	0.03	0.01	0.10	0.60

¹Values are HRs (95% CIs). Intakes were based on the race- and sex-specific Qs. The numbers of deaths from ischemic heart disease were 993 among blacks, 557 among whites, and 2152 among Chinese; those from stroke were 441 among blacks, 131 among whites, and 2919 among Chinese; and those from diabetes were 507 among blacks, 172 among whites, and 897 among Chinese. Q, quintile.

²Adjusted for age, educational attainment, annual household income, marital status, smoking status, smoking pack-years, alcohol consumption, physical activity level, obesity status, healthy eating index, Charlson comorbidity index, intake of total energy, and menopausal status in women.

³Intake of refined carbohydrate was further adjusted for the Chinese population.

⁴To adjust for multiple comparisons across the 3 racial groups, 3 major causes of cardiometabolic deaths, and different choline-related nutrients, *P*-trend values < 0.001 (0.05/45) were considered significant.

TABLE 5 Risk of death from all causes by intakes of choline-related nutrients¹

	Blacks (<i>n</i> = 49,858)			Whites (<i>n</i> = 23,766)			Chinese (<i>n</i> = 134,001)		
	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ²	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ²	Deaths, <i>n</i>	Median, mg/d	HR (95% CI) ^{2,3}
Total choline									
Q1	1477	263.8	1 (ref.)	794	236.9	1 (ref.)	4282	185.7	1 (ref.)
Q2	1542	310.1	1.10 (1.02, 1.18)	706	277.9	0.92 (0.83, 1.01)	3241	245.0	1.02 (0.97, 1.07)
Q3	1616	348.6	1.13 (1.05, 1.21)	798	311.9	1.04 (0.94, 1.15)	2964	289.3	1.02 (0.96, 1.08)
Q4	1737	397.1	1.19 (1.11, 1.27)	820	353.2	1.03 (0.93, 1.13)	2918	336.3	1.03 (0.97, 1.10)
Q5	1828	531.7	1.20 (1.12, 1.29)	891	461.7	1.04 (0.94, 1.15)	3059	414.0	1.08 (1.00, 1.15)
<i>P</i> -trend ⁴			<0.001			0.08			0.04
Phosphatidylcholine									
Q1	1544	123.3	1 (ref.)	772	102.8	1 (ref.)	4279	92.9	1 (ref.)
Q2	1509	161.4	1.04 (0.97, 1.12)	711	134.0	0.96 (0.87, 1.07)	3175	130.9	0.97 (0.93, 1.02)
Q3	1611	194.1	1.10 (1.02, 1.18)	773	161.5	1.04 (0.94, 1.15)	2956	161.8	1.01 (0.96, 1.07)
Q4	1675	236.2	1.13 (1.06, 1.21)	852	197.8	1.09 (0.99, 1.20)	2939	194.8	1.04 (0.98, 1.10)
Q5	1861	353.7	1.20 (1.12, 1.29)	901	301.2	1.07 (0.97, 1.18)	3115	246.2	1.01 (0.95, 1.07)
<i>P</i> -trend ⁴			<0.001			0.02			0.37
Free choline									
Q1	1458	57.0	1 (ref.)	800	54.1	1 (ref.)	3968	39.8	1 (ref.)
Q2	1578	66.3	1.07 (1.00, 1.15)	842	63.9	1.02 (0.92, 1.13)	3041	52.3	0.99 (0.94, 1.04)
Q3	1686	74.3	1.15 (1.07, 1.24)	793	72.0	1.00 (0.90, 1.11)	2876	62.8	1.01 (0.96, 1.07)
Q4	1749	84.6	1.20 (1.12, 1.30)	797	81.4	1.00 (0.90, 1.12)	3048	75.6	1.01 (0.96, 1.07)
Q5	1729	114.7	1.18 (1.09, 1.28)	777	105.4	0.95 (0.85, 1.06)	3531	97.8	1.06 (1.00, 1.12)
<i>P</i> -trend ⁴			<0.001			0.48			0.02
Glycerophosphocholine									
Q1	1593	34.5	1 (ref.)	840	31.1	1 (ref.)	4835	25.0	1 (ref.)
Q2	1548	40.6	0.99 (0.92, 1.06)	801	38.6	1.00 (0.91, 1.10)	3471	32.6	0.94 (0.90, 0.99)
Q3	1638	46.1	1.00 (0.93, 1.08)	819	45.1	1.01 (0.92, 1.12)	3009	39.2	0.91 (0.86, 0.96)
Q4	1689	53.7	1.03 (0.96, 1.10)	791	53.7	0.97 (0.87, 1.07)	2676	46.3	0.86 (0.81, 0.91)
Q5	1732	75.9	1.01 (0.94, 1.09)	758	77.0	0.96 (0.87, 1.07)	2473	58.9	0.87 (0.81, 0.92)
<i>P</i> -trend ⁴			0.40			0.43			<0.001
Sphingomyelin									
Q1	1551	12.8	1 (ref.)	811	12.1	1 (ref.)	4755	5.5	1 (ref.)
Q2	1608	17.6	1.08 (1.01, 1.16)	756	16.3	1.01 (0.92, 1.12)	3375	8.3	0.96 (0.91, 1.00)
Q3	1628	21.3	1.10 (1.03, 1.18)	791	19.6	1.06 (0.96, 1.17)	2977	10.4	0.94 (0.89, 0.99)
Q4	1681	26.0	1.13 (1.06, 1.21)	813	23.6	1.09 (0.98, 1.20)	2753	12.8	0.92 (0.87, 0.97)
Q5	1732	38.1	1.15 (1.07, 1.24)	838	33.8	1.05 (0.95, 1.16)	2604	16.8	0.92 (0.86, 0.98)
<i>P</i> -trend ⁴			<0.001			0.18			0.01
Phosphocholine									
Q1	1548	7.4	1 (ref.)	886	7.3	1 (ref.)	4063	4.7	1 (ref.)
Q2	1577	9.8	1.05 (0.98, 1.13)	804	9.6	0.99 (0.90, 1.09)	3097	7.3	1.01 (0.97, 1.07)
Q3	1691	11.6	1.13 (1.05, 1.22)	816	11.3	1.01 (0.91, 1.12)	2850	9.5	1.01 (0.95, 1.06)
Q4	1692	13.9	1.14 (1.05, 1.23)	778	13.4	0.99 (0.88, 1.10)	2875	12.0	1.00 (0.94, 1.06)
Q5	1692	17.8	1.16 (1.06, 1.26)	725	17.5	0.96 (0.86, 1.09)	3579	16.5	1.05 (1.00, 1.11)
<i>P</i> -trend ⁴			<0.001			0.62			0.08
Betaine									
Q1	1694	104.2	1 (ref.)	893	86.7	1 (ref.)	4059	27.7	1 (ref.)
Q2	1634	137.1	1.03 (0.96, 1.10)	790	111.6	0.94 (0.86, 1.04)	3230	41.3	0.98 (0.94, 1.03)
Q3	1599	165.2	1.01 (0.95, 1.09)	785	133.6	0.95 (0.86, 1.05)	2997	52.2	0.99 (0.94, 1.04)
Q4	1656	205.9	1.03 (0.96, 1.11)	734	166.3	0.86 (0.78, 0.95)	2812	68.3	0.99 (0.94, 1.04)
Q5	1617	287.0	0.99 (0.92, 1.06)	807	240.6	0.95 (0.86, 1.05)	3366	114.0	1.07 (1.02, 1.13)
<i>P</i> -trend ⁴			0.75			0.19			<0.001

¹Intakes were based on the race- and sex-specific Qs. Q, quintile.

²Adjusted for age, educational attainment, annual household income, marital status, smoking status, smoking pack-years, alcohol consumption, physical activity level, obesity status, healthy eating index, Charlson comorbidity index, intake of total energy, and menopausal status in women.

³Intake of refined carbohydrate was further adjusted for the Chinese population.

⁴To adjust for multiple comparisons across the 3 racial groups and different choline-related nutrients, *P*-trend values < 0.003 (0.05/15) were considered significant.

sources vary across racial groups: poultry and processed meat in blacks, dairy and poultry in whites, soy foods and fish in Chinese. We also found that comorbidity status, e.g., the prevalence of diabetes, varied substantially by race. In addition, genetic

variants related to choline metabolism and function may alter the dietary requirement for choline across populations. Previous studies indicated that genetic variants in choline kinase- α , choline dehydrogenase, phosphatidylethanolamine N-methyltransferase,




FIGURE 1 Risk of cardiometabolic and all-cause mortality by total choline intake: stratified analyses. HRs (95% CIs) represent the highest compared with the lowest quintile (race- and sex-specific) of total choline intake. Estimates were adjusted for age, educational attainment, annual household income, marital status, smoking status, smoking pack-years, alcohol consumption, physical activity level, obesity status, healthy eating index, Charlson comorbidity index, intake of total energy, and menopausal status in women; and were stratified by cohort. Intake of refined carbohydrate was further adjusted for the Chinese population. Because the numbers of comparisons were at least doubled in stratified analyses, *P* values for significance for interactions were taken to be half of the corrected *P* values across the 3 racial groups and different choline-related nutrients, thus all <0.0015. CVD, cardiovascular disease.

solute carrier 44A1, and flavin monooxygenase isoform 3 genes were associated with differences in choline dynamics (22, 23). Allele frequencies of those genes significantly differ between European Americans, African descendants, Asian Americans, and Mexican Americans (22), suggesting possible population-specific associations. Future studies on the role of gene–diet–microbiome interactions in choline metabolism and CVD pathogenesis will help elucidate the underlying mechanisms.

Our findings suggest that a history of diabetes or CVD strengthened the choline–mortality association, consistent with results from previous studies (1, 5, 13). Emerging evidence has indicated that higher circulating concentrations of TMAO and its precursors such as choline and betaine were associated with increased risks of CVD morbidity and mortality, especially among individuals with existing cardiometabolic conditions (2, 4, 6, 7). Of note, patients with diabetes, CVD, or chronic kidney disease have shown a higher TMAO concentration than general populations (44–47). It is possible that cardiometabolic diseases may enhance TMAO concentrations, which may be further increased with a high-choline diet. Interestingly, we observed a trend of inverse associations of choline intake with both cardiometabolic and all-cause mortality among heavy drinkers (>2 drinks/d for men and >1 drink/d for women). Considering that choline is an important factor maintaining liver function and the vast majority of choline metabolism occurs in the liver (48), a high choline intake may help recover liver damage from excessive alcohol drinking and, in turn, lead to a reduced risk of

death among heavy drinkers. We had no data on liver function biomarkers in our cohorts, but besides cardiometabolic and all-cause mortality, we also observed a potential inverse association of total choline intake with deaths from liver diseases among heavy drinkers (data not shown). Future studies investigating the health effects of choline-related nutrients need to take into consideration participants' cardiometabolic disease status and alcohol drinking status.

This large, population-based, prospective investigation including diverse populations and detailed information on diet, lifestyle, and medical history allowed us to explore the choline–mortality associations by race and by a range of cardiometabolic risk factors, with comprehensive adjustment for potential confounders. Despite the methodological strengths, we note several limitations of our current study. First, although we used validated FFQs showing high accuracy and reproducibility for major choline/betaine-containing foods (e.g., red meat, eggs, fish, and wheat products) among the southeastern US populations (27) and urban Chinese populations (49, 50), the validity of choline-related nutrient intakes has not been directly assessed in our study populations. Measurement errors in diet assessment might affect the results, but the errors should be nondifferential in our prospective design. Second, owing to a single dietary assessment at baseline, we could not consider dietary changes over time, which might attenuate the overall associations (51). Third, despite our comprehensive adjustments for potential confounders, we cannot rule out residual confounding or unmeasured confounders.




FIGURE 2 Dose–response relation of total choline intake with cardiometabolic and all-cause mortality. HRs (solid line) and 95% CIs (dashed line) were adjusted for race, sex, age, educational attainment, annual household income, marital status, smoking status, smoking pack-years, alcohol consumption, physical activity level, obesity status, healthy eating index, Charlson comorbidity index, intake of total energy, and menopausal status in women; and were stratified by cohort. Intake of refined carbohydrate was further adjusted for the Chinese population. To minimize potential effects of extreme values, participants with the top 1% of total choline intake were excluded from the analysis. The 10th percentile was set as the reference, and 4 knot positions were fitted at the 5th, 25th, 75th, and 95th percentiles.

In summary, high choline intake is associated with increased risk of cardiometabolic mortality, especially for diabetes and IHD mortality and among blacks, Chinese, non-/moderate-drinkers, and individuals with a history of diabetes or CVD. Replacing major food sources of choline (i.e., red meat and eggs) with plant-based foods (e.g., vegetables, nuts, and legumes) may reduce total choline intake. Whether the observed choline–cardiometabolic mortality association may be mediated by gut microbial production of TMAO warrants future studies.

The authors' responsibilities were as follows—DY, LPL, and X-OS: designed the study; LPL, X-OS, WJB, Y-BX, MDS, HL, Y-TG, and WZ: provided essential reagents or essential materials; DY and JJY: performed statistical analysis and drafted the manuscript; DY: had primary responsibility for the final content; and all authors: read and approved the final manuscript. The authors report no conflicts of interest.

References

- Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung Y-M, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011;472:57–63.
- Zeisel SH, Warriar M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. *Annu Rev Nutr* 2017;37:157–81.
- Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* 2013;19:576–85.
- Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. *J Am Heart Assoc* 2017;6(7):e004947.
- Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* 2013;368:1575–84.
- Svingen GFT, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren G, Njølstad PR, Seifert R, Strand E, Karlsson T, et al. Prospective associations of systemic and urinary choline metabolites with incident type 2 diabetes. *Clin Chem* 2016;62:755–65.
- Shan Z, Sun T, Huang H, Chen S, Chen L, Luo C, Yang W, Yang X, Yao P, Cheng J, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. *Am J Clin Nutr* 2017;106:888–94.
- Cho E, Zeisel SH, Jacques P, Selhub J, Dougherty L, Colditz GA, Willett WC. Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study. *Am J Clin Nutr* 2006;83:905–11.
- Patterson KY, Bhagwat SA, Williams JR, Howe JC, Holden JM. USDA database for the choline content of common foods. Release two [Internet]. Beltsville, MD: Agricultural Research Service, USDA; January 2008 [cited 12 July, 2018]. Available from: <https://www.ars.usda.gov/ARUserFiles/80400525/Data/Choline/Choln02.pdf>.
- Bidulescu A, Chambless LE, Siega-Riz AM, Zeisel SH, Heiss G. Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. *BMC Cardiovasc Disord* 2007;7:20.
- Yonemori KM, Lim U, Koga KR, Wilkens LR, Au D, Boushey CJ, Le Marchand L, Kolonel LN, Murphy SP. Dietary choline and betaine intakes vary in an adult multiethnic population. *J Nutr* 2013;143:894–9.
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for thiamin, riboflavin, niacin, vitamin B₆, folate, vitamin B₁₂, pantothenic acid, biotin, and choline [Internet]. Washington (DC): National Academies Press (US); 1998 [cited 14 November, 2018]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK114310/>.

13. Zheng Y, Li Y, Rimm EB, Hu FB, Albert CM, Rexrode KM, Manson JE, Qi L. Dietary phosphatidylcholine and risk of all-cause and cardiovascular-specific mortality among US women and men. *Am J Clin Nutr* 2016;104:173–80.
14. Millard HR, Musani SK, Dibaba DT, Talegawkar SA, Taylor HA, Tucker KL, Bidulescu A. Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study. *Eur J Nutr* 2018;57:51–60.
15. Xu X, Gammon MD, Zeisel SH, Bradshaw PT, Wetmur JG, Teitelbaum SL, Neugut AI, Santella RM, Chen J. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. *FASEB J* 2009;23:4022–8.
16. Chiuve SE, Giovannucci EL, Hankinson SE, Zeisel SH, Dougherty LW, Willett WC, Rimm EB. The association between betaine and choline intakes and the plasma concentrations of homocysteine in women. *Am J Clin Nutr* 2007;86:1073–81.
17. Bertola ML, Pai JK, Cooke JP, Joosten MM, Mittleman MA, Rimm EB, Mukamal KJ. Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease. *Atherosclerosis* 2014;235:94–101.
18. Nagata C, Wada K, Tamura T, Konishi K, Kawachi T, Tsuji M, Nakamura K. Choline and betaine intakes are not associated with cardiovascular disease mortality risk in Japanese men and women. *J Nutr* 2015;145:1787–92.
19. Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT. Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. *Eur J Clin Nutr* 2008;62:386–94.
20. Aron-Wisniewsky J, Clément K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. *Nat Rev Nephrol* 2016;12:169–81.
21. Doré J, Blottière H. The influence of diet on the gut microbiota and its consequences for health. *Curr Opin Biotechnol* 2015;32:195–9.
22. da Costa K-A, Corbin KD, Niculescu MD, Galanko JA, Zeisel SH. Identification of new genetic polymorphisms that alter the dietary requirement for choline and vary in their distribution across ethnic and racial groups. *FASEB J* 2014;28:2970–8.
23. Ganz AB, Cohen VV, Swersky CC, Stover J, Vitiello GA, Lovesky J, Chuang JC, Shields K, Fomin VG, Lopez YS, et al. Genetic variation in choline-metabolizing enzymes alters choline metabolism in young women consuming choline intakes meeting current recommendations. *Int J Mol Sci* 2017;18(2):252.
24. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating health disparities. *J Health Care Poor Underserved* 2010;21:26–37.
25. Shu X-O, Li H, Yang G, Gao J, Cai H, Takata Y, Zheng W, Xiang Y-B. Cohort profile: the Shanghai Men's Health Study. *Int J Epidemiol* 2015;44:810–18.
26. Zheng W, Chow W-H, Yang G, Jin F, Rothman N, Blair A, Li H-L, Wen W, Ji B-T, Li Q, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. *Am J Epidemiol* 2005;162:1123–31.
27. Buchowski MS, Schlundt DG, Hargreaves MK, Hankin JH, Signorello LB, Blot WJ. Development of a culturally sensitive food frequency questionnaire for use in the Southern Community Cohort Study. *Cell Mol Biol (Noisy-le-grand)* 2003;49:1295–304.
28. Schlundt DG, Buchowski MS, Hargreaves MK, Hankin JH, Signorello LB, Blot WJ. Separate estimates of portion size were not essential for energy and nutrient estimation: results from the Southern Community Cohort food-frequency questionnaire pilot study. *Public Health Nutr* 2007;10:245–51.
29. Yu D, Sonderman J, Buchowski MS, McLaughlin JK, Shu X-O, Steinwandel M, Signorello LB, Zhang X, Hargreaves MK, Blot WJ, et al. Healthy eating and risks of total and cause-specific death among low-income populations of African-Americans and other adults in the southeastern United States: a prospective cohort study. *PLoS Med* 2015;12:e1001830.
30. Signorello LB, Munro HM, Buchowski MS, Schlundt DG, Cohen SS, Hargreaves MK, Blot WJ. Estimating nutrient intake from a food frequency questionnaire: incorporating the elements of race and geographic region. *Am J Epidemiol* 2009;170:104–11.
31. Yang Y, Wang G, Pan X, editors. *China food composition tables*. Beijing: Beijing Medical University Press; 2002.
32. US Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for standard reference, release 25 [Internet]. Beltsville, MD: Methods and Application of Food Composition Laboratory, Agricultural Research Service, USDA; 2012 [cited 12 July, 2018]. Available from: <http://www.ars.usda.gov/nea/bhnrc/mafcl>.
33. Shrubsole MJ, Shu XO, Li H-L, Cai H, Yang G, Gao Y-T, Gao J, Zheng W. Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. *Am J Epidemiol* 2011;173:1171–82.
34. Yu D, Shu X-O, Xiang Y-B, Li H, Yang G, Gao Y-T, Zheng W, Zhang X. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. *J Nutr* 2014;144:2034–40.
35. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. *Am J Clin Nutr* 1997;65:1220S–8S; discussion 1229S–31S.
36. Yu D, Zhang X, Xiang Y-B, Yang G, Li H, Gao Y-T, Zheng W, Shu X-O. Adherence to dietary guidelines and mortality: a report from prospective cohort studies of 134,000 Chinese adults in urban Shanghai. *Am J Clin Nutr* 2014;100:693–700.
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
38. Yu D, Shu X-O, Li H, Xiang Y-B, Yang G, Gao Y-T, Zheng W, Zhang X. Dietary carbohydrates, refined grains, glycemic load, and risk of coronary heart disease in Chinese adults. *Am J Epidemiol* 2013;178:1542–9.
39. Yu D, Zhang X, Shu X-O, Cai H, Li H, Ding D, Hong Z, Xiang Y-B, Gao Y-T, Zheng W, et al. Dietary glycemic index, glycemic load, and refined carbohydrates are associated with risk of stroke: a prospective cohort study in urban Chinese women. *Am J Clin Nutr* 2016;104:1345–51.
40. Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. *Annu Rev Nutr* 2006;26:229–50.
41. Fischer LM, daCosta KA, Kwock L, Stewart PW, Lu T-S, Stabler SP, Allen RH, Zeisel SH. Sex and menopausal status influence human dietary requirements for the nutrient choline. *Am J Clin Nutr* 2007;85:1275–85.
42. Zeisel SH, da Costa K-A. Choline: an essential nutrient for public health. *Nutr Rev* 2009;67:615–23.
43. Meyer KA, Shea JW. Dietary choline and betaine and risk of CVD: a systematic review and meta-analysis of prospective studies. *Nutrients* 2017;9(7):711.
44. Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S, Hartmane D, Pugovics O, Erglis A, Liepinsh E. Diabetes is associated with higher trimethylamine N-oxide plasma levels. *Exp Clin Endocrinol Diabetes* 2016;124:251–6.
45. Mente A, Chalcraft K, Ak H, Davis AD, Lonn E, Miller R, Potter MA, Yusuf S, Anand SS, McQueen MJ. The relationship between trimethylamine-N-oxide and prevalent cardiovascular disease in a multiethnic population living in Canada. *Can J Cardiol* 2015;31:1189–94.
46. Tang WHW, Wang Z, Li XS, Fan Y, Li DS, Wu Y, Hazen SL. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. *Clin Chem* 2017;63:297–306.
47. Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, Holmes DT, Madore F, Clase CM, Rigatto C, et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. *Kidney Int* 2016;89:1144–52.
48. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. *Curr Opin Clin Nutr Metab Care* 2013;16:339–45.
49. Villegas R, Yang G, Liu D, Xiang Y-B, Cai H, Zheng W, Shu XO. Validity and reproducibility of the food-frequency questionnaire used in the Shanghai Men's Health Study. *Br J Nutr* 2007;97:993–1000.
50. Shu XO, Yang G, Jin F, Liu D, Kushi L, Wen W, Gao Y-T, Zheng W. Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women's Health Study. *Eur J Clin Nutr* 2004;58:17–23.
51. Hu FB, Satija A, Rimm EB, Spiegelman D, Sampson L, Rosner B, Camargo CA, Stampfer M, Willett WC. Diet assessment methods in the Nurses' Health Studies and contribution to evidence-based nutritional policies and guidelines. *Am J Public Health* 2016;106:1567–72.